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Proton therapy is associated with signiﬁcant beneﬁt in terms of normal tissue sparing
and potential radiation dose escalation for many patients with malignant diseases. Due to
recognition of these qualities, the availability of this technology is increasing rapidly, both
through increased availability of large centers, and with the possibility of smaller, lower
cost proton therapy centers. Such expansion is associated with increased opportunity to
provide this beneﬁcial technology to larger numbers of patients; however, the importance
of careful treatment planning and delivery, deliberate patient selection, rigorous scientiﬁc
investigation including comparison to other technologies when possible, and mindfulness
of ethical issues and cost effectiveness must not be forgotten. The obligation to move
forward responsibly rests on the shoulders of radiation oncologists around the world. In
this article, we discuss current use of proton therapy worldwide, as well as many of the
factors that must be taken into account during rapid expansion of this exciting technology.
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INTRODUCTION
Although proton therapy for treatment of malignant disease is not
a new concept, and has been in fact employed clinically since the
1970s, interest in its use is rapidly gaining momentum as clinical
technology becomes more widespread and available. Currently,
proton therapy centers designed speciﬁcally for treatment of can-
cer patients exist in most regions of the United States, as well
as several areas in Europe and Asia. Accompanying the availabil-
ity of these centers is the promise of smaller, more economical
machines that may soon be available in numerous other centers.
As the radiation oncology community prepares for rapid changes
that are occurring and promise to continue to occur in the ﬁeld of
proton therapy, understanding of the many complexities of center
design, treatment planning, and treatment delivery is essential. In
the following pages, several of these issues will be outlined, along
with current use and data with regard to proton therapy, future
goals with regard to this technology, and limitations that may be
foreseen at this point.
THE PHYSICAL BENEFIT OF THE PROTON BEAM
The physical properties of protons allow achievement of a very
simple beneﬁt: reduction in radiation delivered outside of the tar-
get volume. Photons have neither mass nor charge, and as a result
traverse the patient, depositing both entrance and exit dose. In
contrast, protons are relatively heavy and carry a positive charge.
Together, these properties result in signiﬁcant stopping power of
the proton beam. When a given proton stops within tissue, it
deposits the majority of its energy, creating the proverbial Bragg-
peak, and eliminating exit dose entirely. With careful planning,
Bragg-peaks may be aligned to create a spread-out Bragg-peak
(SOBP; Figure 1). The SOBP may be carefully positioned so
that the vast majority of dose is delivered to the tumor, with
no radiation delivered distally. The implications of this unique
quality are quite far reaching. Reducing exit dose within a child’s
brain may allow radiation to be delivered to many fewer devel-
oping neurons than has been previously possible. Use of proton
therapy for spinal lesions may allow elimination of dose to vis-
ceral organs, including heart, lung, bowel, and organs of fertility
and reproduction. Proton therapy for treatment of sarcomas may
allow delivery of high radiation doses with essential sparing of
normal tissue. Due to increased tissue sparing with use of proton
therapy, this modality may also be used to escalate radiation dose
delivered. Certainly, these opportunities are extremely appealing
and, in combination with increased accessibility, have prompted
increasing use of proton therapy.An analysis of the currently avail-
able literature examining clinical use of proton therapy, as well
as certain of the scientiﬁc and treatment limitations of proton
therapy are essential to our delineation of future needs.
CURRENT USE AND PUBLISHED DATA REGARDING USE OF
PROTON THERAPY
LIMITATIONS TO DATA COLLECTION AND ANALYSIS
Certainly, the advent of any new technology warrants rigorous sci-
entiﬁc investigation of risks and beneﬁts associated with its use.
To most radiation oncologists and physicists, the beneﬁt of pro-
ton therapy in many clinical cases is without question; protons
allow sparing of normal tissue, which is unarguably beneﬁcial to
patients. Indeed, to a radiation oncologist experienced in delivery
of proton therapy, the decision of whether or not to employ it in a
given case is analogous to a surgeon’s decision regarding the choice
of a particular scalpel or cautery device. Having said this, a certain
onus rests on practitioners within the ﬁeld of radiation oncology
to provide scientiﬁc support for treatment decisions; additionally,
the sheer cost of proton therapy requires that evidence of beneﬁt
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FIGURE 1 | Graphic demonstration of the rapid dosimetric peak and fall-off of the Bragg-peak; the alignment of many Bragg-peaks may allow creation
of the spread-out Bragg-peak (SOBP) that allows deposition of radiation in a specific location with essentially no dose deposited beyond this.
be provided to justify the use of this technology for patients who
may beneﬁt from it, and to limit the use of this resource to use for
those who will achieve improved outcomes as a result.
Although proton therapy has been used clinically for the past
40 years (Skarsgard, 1998), small patient numbers have historically
limited publication of large studies. Most published data examin-
ing clinical use of proton therapy are single institution series.While
these publications, many of which will be discussed further below,
are of great value, they do not represent randomized controlled
trials (RCT) – held to be the gold standard for evaluation and
comparison of treatment techniques. Limitations to conducting
RCT evaluating the role of proton therapy compared to photon
therapy are numerous, and include limitations in patient numbers,
resource access, and ethics of randomization to a modality felt to
be inferior by much of the radiation oncology community.
In addition to these limitations is the sheer amount of time
that may be required to fully assess outcomes for patients after any
type of radiation therapy. This limitation may apply to both retro-
spective and prospective analyses, which remain relatively sparse
within the literature. Assessing disease-related outcomes is criti-
cal for any oncologic trial; the evaluation of long-term and late
effects is, however, potentially more pertinent to evaluation of a
technology whose main beneﬁt is reduction of normal tissue dose.
Long-term and late effects may take many years to develop, and so
careful, long-term follow-up is required and may be particularly
complex for patients who are treated at a tertiary referral proton
center and then return to their home institutions. In reality, as use
of proton therapy becomes rapidly more widespread, long-term,
and late effects data will simply not be available as quickly as they
are needed.
Fortunately, many large institutions and cooperative groups
have come to formally recognize the need for rigorous data col-
lection and publication, and great progress is being made in this
arena. The Radiation TherapyOncologyGroup (RTOG) andChil-
dren’s Oncology Group (COG) are employing proton therapy
in several cooperative trials, and many large proton centers are
focused on publishing high-quality data regarding proton ther-
apy. At our own institution, for example, every patient treated
with proton therapy is enrolled on a clinical trial; some patients
may be enrolled on cooperative group studies, while others are
enrolled on single institution experimental protocols or data reg-
istries. Furthermore, representatives from several large institutions
are dedicated to collaborative work with one another in order
to facilitate gathering and publication of robust data from mul-
tiple institutions. In the future, these resources may hopefully
allow for analysis and publication of large comparative datasets;
a discussion of the currently available literature, with focus on
publications that are clinical in nature, rather than dosimetric or
physics comparisons follows below.
CURRENT TECHNICAL USE AND LIMITATIONS
The challenges in conducting randomized studies extend beyond
the above issues due to different stages of development of pro-
ton versus photon therapy. The vast majority of institutions
currently delivering proton therapy make use of double scat-
tered technology. Scattered beam techniques allow delivery of
three-dimensional conformal proton therapy (3D-CPT), some-
what analogous to standard three-dimensional conformal radi-
ation (3D-CRT), with the addition of increased distal stopping
power. Although double scattering offers signiﬁcant tissue sparing
at the distal edge of the beam, proximal and lateral beam con-
formality may be reduced in some cases compared to intensity
modulated radiation therapy (IMRT) using photons. This may be
of signiﬁcance in clinical situations inwhich concave tumor targets
are situated next to neighboring organs, such as the liver, kid-
ney, or brainstem. In contrast, intensity modulated proton therapy
(IMPT), employing a scanning beam,allows distribution of Bragg-
peaks in three-dimensions through the target volumes, allowing
improved conformality, and sparing of normal structures (Lomax
et al., 2004a). The majority of proton therapy centers worldwide
offer scattered proton beams, although the number with access
to scanning beam is increasing. The vast majority of published
data, as such, regards use of scattered beam technology, although
the Paul Scherrer Institute (PSI) in Villagen, Switzerland has pub-
lished their experience treating several tumor types with scanning
proton beams/IMPT (Lomax et al., 2004b; Timmermann et al.,
2006). As scanning beam technology becomes more widely avail-
able, a lag is expected to exist within the literature as institutions
and cooperative groups gather data with its use, analogous to the
delay observed in publication of data after use of IMRT compared
to 3D conformal radiotherapy in the photon literature.
Additionally, availability of improved imaging in proton treat-
ment room may create new opportunities in terms of increasing
the accuracy of proton therapy due to better understanding and
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management of uncertainties related to the proton beam. As
randomized studies tend to be multicentered, the availability of
equally advanced technologies at all centers participating is opti-
mal, however, centers are unique in terms of the technologies that
they are able to offer. As a result, true assessment of the poten-
tial of proton therapy may not be possible until a time when the
most advanced technologies may be broadly available for use in
the randomized trials meant to evaluate them. Again, this must be
expected to introduce a delay within the published literature.
PUBLISHED CLINICAL DATA
Central nervous system
The brain and spinal cord are currently the sites for which use
of proton therapy is most well-supported by the literature and
used clinically. In 2004, St Clair and colleagues demonstrated
clear dosimetric advantage of proton therapy for treatment of
patients with medulloblastoma requiring craniospinal irradiation
and boost to the posterior fossa. Advantages included reduction
of dose to the cochlea and heart, with expectations for transla-
tion to improved outcome with regard to hearing, endocrine, and
cardiac function (St Clair et al., 2004). In 2008, Merchant and
colleagues demonstrated through dose–cognitive effects models
that reduction in integral radiation dose to the pediatric brain
could be expected to translate to reduction in IQ deﬁcit long
recognized to result from radiation for childhood brain tumors
(Merchant et al., 2008). Publications such as these have prompted
great interest in use of proton therapy for central nervous system
(CNS) tumors. Since that time, numerous dosimetric studies have
been published demonstrating reduction of dose to normal brain
and nearby organs at risk with proton therapy as compared to
photon therapy. Clinical data have become more available over
the past 3–5 years, particularly within the pediatric population.
MacDonald and colleagues have recently published early clinical
outcomes of children treated with 3D-CPT at the Massachusetts
General Hospital (MGH) for ependymoma (MacDonald et al.,
2008) and CNS germ cell tumors (MacDonald et al., 2011). Excel-
lent clinical outcomes were demonstrated compared to historical
controls, including overall survival of 89 and 100%, respectively,
with median follow-up greater than 2 years, accompanied by sub-
stantial normal tissue sparing with proton therapy as compared
to IMRT. Craniopharyngioma is a particularly attractive tumor
for use of proton therapy due to its slow-growing nature, devel-
opment in children, and potential to cause severe damage. The
dosimetric superiority of proton therapy for treatment of cran-
iopharyngioma has been demonstrated (Boehling et al., 2011),
and multiple groups have published clinical data supporting use
of proton therapy in this clinical setting and demonstrating 5 year
local control rates of over 90% (Fitzek et al., 2006; Luu et al., 2006).
Winkﬁeld et al. (2009) speciﬁcally investigated changes in cyst size
and dimension during proton radiotherapy and reported need for
changes in proton planning due to cyst changes in 6 of 17 patients.
Certainly, this report should be kept in mind during treatment
of this complex tumor, with routine surveillance of cyst size and
dimension performed throughout the course of therapy.
Certainly use of proton therapy for treatment of the entire cran-
iospinal axis is highly appealing because it results in reduction of
radiation dose to numerous normal structures (Yuh et al., 2004;
Krejcarek et al., 2007). This technique may be quite complicated,
requiring matching of multiple ﬁelds, and impacted by limitations
of ﬁeld length. Modiﬁcation of a 3D-CPT technique to reduce lens
dose has recently been reported (Cochran et al., 2008), and a sin-
gle case in the literature using spot-scanning proton radiation to
deliver CSI is available (Timmermann et al., 2007).
Data supporting use of proton therapy for adult CNS tumors is
somewhat more limited. Ronson et al. (2006) have demonstrated
excellent outcomes after proton therapy for pituitary adenomas,
and data from the PSI support use of proton therapy for treat-
ment of meningioma (Weber et al., 2004). Mizumoto et al. (2010)
have recently reported the results of a phase I/II trial evaluating
the role of concomitant proton boost therapy with dose esca-
lation to 96.6Gy (RBE) for glioblastoma multiforme (GBM) in
adult patients. This group demonstrated excellent median and
overall survival rates compared to historical controls, and this
study represents one of the few available examining clinical dose
escalation with proton therapy in the CNS.
Skull base and head and neck tumors
Radiation to the head and neck using any available technology
remains complex, due mainly to complex target shape and delin-
eation, close proximity of organs at risk to areas needing treatment,
and need for relatively high-dose delivery. Again, several dosimet-
ric studies have been performed evaluating proton therapy, for the
most part 3D-CPT, compared to IMRT. These support the ability
of proton therapy to result in sparing of normal tissue when radi-
ation is required to the paranasal sinuses (Miralbell et al., 1992;
Mock et al., 2004; Chera et al., 2009), nasopharynx (Brown et al.,
1989; Taheri-Kadkhoda et al., 2008; Widescott et al., 2008), and
oropharynx/hypopharynx/larynx (Slater et al., 1992; Cozzi et al.,
2001; Johansson et al., 2004; Steneker et al., 2006). Lomax et al.
(2003) have also demonstrated the potential for dose escalation
during treatment of head and neck cancers with proton therapy
based on dosimetric work.
Strong clinical data exists with regard to treatment of skull
base chordoma and chondrosarcoma with proton therapy, with
investigators from PSI having published reports of experiences at
their center treating both pediatric and adult patients with spot-
scanning proton therapy: In 2009, Ares and colleagues reported
on 64 patients treated with spot-scanning technique for skull base
tumors, with median follow-up of 38months. The authors report
local control rates at 5 years of 81% (chordomas) and 94% (chon-
drosarcomas), with 94% rate of freedom from high-grade toxicity
(Ares et al., 2009). A report of children and adolescents treated
with similar techniques demonstrates no treatment failures and
no severe late toxicities (Rutz et al., 2008). Interestingly, dosimet-
ric work by Torres et al. (2009) suggests that use of combined
proton and IMRT plans for skull base chordomas may result in
the best tumor coverage and conformality compared to 3D-CPT
alone. Ares and colleagues include a detailed review of the liter-
ature within their report, in which they compare their ﬁndings
to those from several other institutions and report inferior 5-year
progression-free survival (PFS) with use of photon irradiation
compared to their own ﬁndings after proton therapy; speciﬁcally,
Zorlu et al. (2000) have reported 5-year PFS of 23% using mod-
ern diagnostic and photon radiotherapy techniques for treatment
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of skull base tumors. An exception to this may be the use of
fractionated stereotactic radiosurgery for treatment of small chon-
drosarcomas. Local control rates of 100% are reported in the
literature in this speciﬁc clinical setting, but remain more dis-
appointing for chordomas (30–50%; Debus et al., 2000; Krishnan
et al., 2005). Of note,Nikoghosyan et al. (2010) report that a phase
III trial of proton versus carbon ion therapy in patients with chor-
doma of the skull base is currently underway at the University of
Heidelberg.
Clinically, a pilot study by Zenda et al. (2010) has recently
demonstrated that hypofractionated proton therapy may be clin-
ically promising in treatment of mucosal melanomas of the head
andneck. This data is supported by recentmeta-analysis of particle
therapy formucosalmelanomas of the head andneck,demonstrat-
ing signiﬁcantly improved 5-year OS with particle therapy versus
photon therapy (Ramaekers et al., 2011).
Clinical data is available regarding use of proton therapy for
pediatric cancers of the head and neck,most commonly sarcomas.
Investigators from MGH have demonstrated improved normal
tissue sparing during treatment of parameningeal and orbital
rhabdomyosarcoma (Yock et al., 2005; Kozak et al., 2009); partic-
ularly of note is dose reduction of contralateral tissues, including
the orbit, cochlea, and parotid, when protons are employed versus
IMRT.
Clinical data with regard to treatment of squamous cell car-
cinoma of the head and neck is available in small numbers.
Treatment outcomes were reported for 20 patients with primary
sphenoid sinus malignancy, treated to a median dose of 76Gy
(RBE). The authors report 2-year local control of 86%, and con-
clude that proton therapy may result in excellent LC for these
patients (Truong et al., 2009).A recentmeta-analysis demonstrates
improved LC for paranasal and sinonasal cancers with use of pro-
ton therapy compared to IMRT; however, the same group found
no improvement for patients with cancers of other sites within
the head and neck (Ramaekers et al., 2011). The complex nature
of treatment volumes for head and neck cancers, which are often
large, convex volumes which change signiﬁcantly from superior
most to inferior most extent of treatment, makes the conformal
nature of IMRT appealing for their treatment. In many cases,
IMRT allows signiﬁcantly improved conformality compared to
3D-CPT; however, if and when IMPT matures and becomes more
widely available, the full beneﬁts of proton therapy for normal tis-
sue sparing are expected to be observed for this group of patients.
IMPTwill allowboth reduction in exit dose and shapingof thepro-
ton beam in a way that is not possible with 3D-CPT and promises
maximal gain at the oral cavity level, potentially increasing patient
tolerance of concomitant chemotherapy. Further investigation of
clinical outcomes using IMPT for treatment of head and neck
tumors will be essential for proper evaluation of proton therapy
in this clinical setting.
Abdomen and pelvis
The diverse nature of tumors of the abdomen and pelvis requires
heterogeneous treatment methodology; however, many tumors
occur in these regions that may be well-suited to proton ther-
apy. These include, and are not limited to, tumors of the prostate
gland, as well as localized tumors within the abdomen and pelvis
and tumors of bone and muscle. Prostate cancer is certainly an
appealing use of this modality, due to a combination of relatively
high required dose of >70Gy and the proximity of the prostate to
normal, more radiosensitive structures, most notably the rectum,
but including the bladder, femoral heads, and bowel. Addition-
ally, dose escalation trials have demonstrated potential beneﬁt for
prolonging biochemical failure free survival (BFFS), and the pos-
sibility of delivering higher doses with decreased risk of damage
certainly exists with proton therapy. In a collaborative randomized
controlled trial, Proton Radiation Oncology Group (PROG) 95-
09, MGH, and Loma Linda University Medical Center conducted
an investigation of dose escalation using proton therapy for men
with clinically localized prostate cancer; men were treated with
combination of proton and photon radiation to a total dose of
either 70.2 or 79.2Gy (RBE). The authors demonstrated a 49%
reduction in BFFS with the use of dose escalation with only a 1%
associated increase in acute or late urinary or rectal toxicity (Ziet-
man et al., 2005). No increase in patient-reported symptoms in the
high-dose arm compared to the lower dose arm was reported in a
separate quality of life analysis (Talcott et al., 2010). Men with low-
to intermediate-risk prostate cancer treated on the high-dose arm
of PROG 95-09 were recently compared in a case-matched analy-
sis to men treated with brachytherapy at the MGH. No difference
in BFFS was demonstrated between the two groups; however, the
authors note that no quality of life analysis was possible, and that
brachytherapy has historically been associated with increase in
obstructive voiding symptoms compared to external beam radi-
ation (Chen et al., 2009). In light of excellent quality of life data
with proton-based dose escalation reported by Talcott et al. (2010),
patient-reported outcomes following brachytherapy are particu-
larly important during any meaningful comparison. Also within
the setting of prostate cancer, other groups have demonstrated
very low incidence of grade 2 or greater rectal and/or (Nihei et al.,
2010), and feasibility of dose escalation to >80Gy (Coen et al.,
2010). Several centers in the US and worldwide routinely employ
proton therapy for treatment of localized prostate cancer at this
point, and results of larger trials are currently pending.
Radiation of the pediatric pelvis poses signiﬁcantly greater risk
than is seen with adults due to the growing nature of the bony
pelvis in a child. In addition, reproductive and endocrine organs
may be of particular importance for sparing in young children. In
a small group of children treated with proton therapy for rhab-
domyosarcoma of the bladder and prostate, signiﬁcant decrease
in mean organ dose to the bladder, testes, femoral heads, growth
plates, and pelvic bones has been observed (Cotter et al., 2010),
and similar results have been demonstrated dosimetrically by
other groups, including decreased ovarian dose, during treatment
of pelvic sarcomas (Lee et al., 2005). Radiotherapy is currently
widely employed for treatment of most rhabdomyosarcomas, and
unresectable, pelvic Ewing’s sarcoma. Scant evidence exists that
high-doses of radiation may have curative potential for osteosar-
coma. A trial is currently underway examining the potential of
heavy ion therapy in this clinical situation (Blattmann et al., 2010).
Chest/lung
Several clinical studies have investigated the role of proton
therapy in treatment of non-small cell lung cancer (NSCLC).
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Hypofractionated, dose escalated, proton beam therapy for
patients with early stage lung cancer has been shown to pro-
vide excellent clinical results in several phase I and II trials
(Hata et al., 2007; Iwata et al., 2010; Nakayama et al., 2010).
For early stage patients, dosimetric comparison of proton-based
stereotactic body radiotherapy (SBRT) to photon-based SBRT
demonstrates decreased radiation to organs at risk with use of
protons, including uninvolved lung tissue (Hoppe et al., 2010). In
a recent meta-analysis comparing radiation with photons, pro-
tons, and carbon-ions for treatment of stage I NSCLC, 5 year
OS was 20% after conventional photon radiotherapy compared
to 40–42% after proton therapy, carbon ion therapy, or stereo-
tactic body irradiation. The authors caution that their results
are limited by small patient numbers and follow-up time (Grut-
ters et al., 2009). The role of proton therapy for treatment
of more advanced NSCLC, requiring concurrent chemother-
apy, is evolving. Sejpal et al. (2011) compared such patients
receiving proton therapy to historical results after IMRT or 3D-
CRT and demonstrated decreased risk of severe pneumonitis
and esophagitis in the former group. The authors note that a
prospective, randomized trial investigating the same question is
underway.
The role of proton therapy in treatment of other cancers of
the mediastinum and lung is emerging with an investigative role.
Clinical data from MD Anderson Cancer Center demonstrates
reduced dose to lung, esophagus, heart, and coronary arteries
using 3D-PBT for treatment of mediastinal lymphoma (Li et al.,
2010). Certainly, use of proton therapy to treat mediastinal dis-
ease may be particularly attractive if it is also found to reduce
breast dose; this may be of particular importance for young girls
and women, recognized to be at signiﬁcantly increased risk for
breast cancer following treatment for Hodgkin’s disease. A dosi-
metric planning study from the University of Zurich has demon-
strated that proton beam therapy may allow reduction in dose to
organs at risk during treatment of mesothelioma after extrapleural
pneumonectomy. Although this technique is promising from a
dosimetric standpoint, the authors note that changing air cavi-
ties had signiﬁcant impact on proton plans; the role of proton
therapy in this complex treatment paradigm has yet to be deﬁned
clinically.
Delivery of proton therapy to tumors in the chest brings to
light many issues of concern with regard to target motion and
heterogeneity, both of which will be discussed further below.
Breast
Data with regard to use of proton therapy in treatment of breast
cancer are relatively limited. Some dosimetric justiﬁcation may
exist for delivery of “boost” radiation to the tumor bed after radi-
ation to the intact breast (Toscas et al., 2010), and for use of
IMPT for delivery of whole breast radiation for patients with left
sided breast cancer (Ares et al., 2010). This technique may allow
improved dose delivery to the whole breast with sparing of heart
and lung; however, it must be employed with great caution to
avoid under-dosing of the chest wall and proximal breast tissue
during normal respiration. The MGH has published their experi-
ence treating 20 early stage breast cancer patients with accelerated
partial breast proton irradiation (APBI). With limited follow-up,
disease-related outcomes were excellent; however, severe moist
desquamation was described in 22% of cases (Kozak et al., 2006).
Although further investigation of proton therapy in this spe-
ciﬁc clinical setting may be warranted, no clear beneﬁt for use
of protons over other methods of delivery of APBI has been
demonstrated at this point.
A word on pediatrics
Throughout the above discussion, the beneﬁt of proton therapy
in treatment of pediatric tumors is noted again and again. When
considered both clinically and dosimetrically, the beneﬁt of spar-
ing normal, growing tissue in this unique population is inarguable.
It is the opinion of these authors that proton therapy should be
considered and utilized for all pediatric patients needing curative
irradiation, providing that this is technically feasible. The pediatric
oncology community widely recognizes the negative impact of
radiation to normal tissues in childhood, and use of technology to
reduce the volume of normal tissue exposed is warranted without
question.
POTENTIAL LIMITATIONS: COST EFFECTIVENESS AND
ISSUES IN TREATMENT PLANNING AND DELIVERY
COST EFFECTIVENESS
The message from many of the published clinical and dosimet-
ric studies described above is consistent: In many cases, proton
therapy offers the ability to deliver equivalent or higher radia-
tion doses with sparing of normal tissue. This beneﬁt is expected
to be magniﬁed as scanning beam technology becomes more
widely available and allows delivery of IMPT. This statement
likely appears redundant to the reader by this point, and begs
the question of why proton therapy is not routinely employed
for all patients. Certainly, the cost effectiveness of this modal-
ity has yet to be fully elucidated, and is much more complex
than a question with a dichotomous answer. For example, pro-
ton therapy for childhood medulloblastoma has been associ-
ated with 23,600C in cost-savings per patient, mainly due to
decreased IQ losses and growth hormone deﬁciency (Lundkvist
et al., 2005a). In contrast, some groups have raised concerns that
proton therapy may not be cost effective for men with prostate
cancer (Konski et al., 2007). Analysis of the cost effectiveness
of a center treating patients with multiple types of cancer has
demonstrated potential for cost-savings; however, the authors note
that multiple uncertainties are included in this analysis, includ-
ing the amount of value placed on quality of life year (QALY)
per patient (Lundkvist et al., 2005b). Ultimately, of course, cost
effectiveness can only be completely understood when compar-
ative outcomes analyses are available; as described above, we
as a community, eagerly await much of this data. Certainly,
accurate cost-effectiveness analyses may be useful for consid-
eration not only by treating centers but by third-party payers.
Other types of cost-effectiveness analyses that would be use-
ful moving forward include examination of cost effectiveness
of centers in close proximity to one another, the most appro-
priate worldwide distribution of proton and particle therapy
centers, and changes in cost effectiveness based on age, which
may be impacted by life expectancy and second malignancy
risk.
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TREATMENT PLANNING AND DELIVERY
The complicated nature of treatment planning and delivery must
be taken into account by any center delivering or planning to
deliver proton therapy. Unique patient immobilization devices
compatible with both simulation and treatment delivery hard-
ware must be utilized; although these may vary among centers,
their essential nature must not be undervalued. Devices employed
generally need to be more robust than those utilized during pho-
ton therapy due to the precise nature of dose deposition when
protons are used. These authors advocate strong physics pres-
ence at the time of simulation and during the entire treatment
planning process for proton or particle therapy in order to assist
with optimal patient immobilization and accurate treatment plan
development. We also recommend strict adherence to the guide-
lines for treatment planning outlined within the International
Commission on Radiation Units and Measurements Report 78
(2007).
Beyond immobilization of the patient is the need for deliber-
ate limitation of motion of the treatment target. Potential risks
of under and overdosing are of perhaps greatest importance dur-
ing consideration of use of proton therapy for moving targets
such as prostate and lung tumors. During treatment of the for-
mer, changes in bladder and rectal position may greatly impact
the position of the prostate itself. The use of a rectal balloon has
been demonstrated to decrease the clinical signiﬁcance of any such
motion (Both et al., 2010). During treatment of thoracic tumors,
technology must be employed to account for respiratory motion,
and may include breath holding techniques, target expansion to
create an internal target volume (ITV), and/or four-dimensional
CT scanning, planning, and treatment delivery.
Treatment of tumors within the chest may also be made com-
plicated by the heterogeneous nature of tissues within the thorax.
Density variations within the path of the proton beam may cause
widening of the distal fall-off of the Bragg-peak. This may be
particularly problematic within lung tissue, and may result in
greater exposure of normal lung tissue than desired or expected
(Sawakuchi et al., 2008). Novel methods of accounting for het-
erogeneity have been proposed and treating centers must verse
themselves in these methods in order to deliver the best and most
precise treatment in any location of the body. Other circumstances
in which heterogeneity may be particularly problematic include
treatment of the head and neck near an air-ﬁlled sinus, treatment
in the presence of hardware that may affect beam distribution, and
treatment of the pelvis when air may be variably present within the
bowel. During the lattermost circumstance, signiﬁcant intrafrac-
tion variationmay further complicate treatment delivery andmust
be accounted for.
Variability in target position may be signiﬁcantly impacted by
the length of time required to deliver a single fraction. Interest-
ingly, the complicated natures of treatment planning and delivery,
as well as cost effectiveness, converge at the point of discussion of
the time required to deliver treatment to an individual patient.
Increased time for fraction delivery has been demonstrated to
result in potentially increased target motion (Both et al., 2010).
Additionally, longer table time per patient per day results in
decreased numbers of patients who may be treated on a given
day at a given center, limiting throughput. In response to both
of these factors, many centers employ a methodology in which
only certain subsets of ﬁelds that are part of a proton plan are
treated each day. The appropriateness of this technique is some-
what unique to proton/particle therapy; in contrast to photon
radiation plans, when multiple beams are required to provide
target coverage, proton plans make use of several beams, each
of which is robust in and of itself to provide adequate dose to
the target volume, although dose to normal structures may dif-
fer signiﬁcantly from ﬁeld to ﬁeld within a given plan. Treating a
subset of ﬁelds limits daily table time per patient, which may be
beneﬁcial in terms of target motion, patient quality of life, and
cost effectiveness. Engelsman et al. (2010) recently analyzed the
radiobiologic impact of this technique for patients being treated
with proton therapy for skull base, lung, pancreatic, and prostate
tumors. For many patients, signiﬁcant variability in dose to organs
at risk was described, which may require that speciﬁc variability
among treatment ﬁelds be taken into account in the future when
this technique is employed. Treating a subset of ﬁelds is not an
option when pencil beam scanning is employed, and therefore
automated imaging and alignment along with fast delivery tech-
niques are required in order to achieve quality safety and cost
effectiveness of treatments with pencil beam scanning across the
entire body.
ETHICAL ISSUES: USE OF LIMITED RESOURCE
Due in part to the limitations discussed above, proton therapy
remains a limited resource that cannot be made available to all
patients. In addition, proton therapy is not expected to offer ben-
eﬁt to all patients, and clinicians must be constantly mindful
of this fact when determining treatment technique. At our own
center, including many others, no patient is planned to receive
proton therapy without the approval of a multidisciplinary com-
mittee that meets weekly. The committee’s goals are to take into
account the relative beneﬁt (or lack thereof) of protons for a cer-
tain patient, as well as overall prognosis and other factors that may
determine suitability such as technical feasibility. These authors
have found this approach to optimize equitable and proper dis-
tribution of this limited resource, while minimizing individual
physician bias.
THE FUTURE OF PROTON THERAPY
Proton therapy is a technology that offers clear beneﬁt to many
cancer patients; however, its use is complicated by technical issues,
as well as cost and availability worldwide. As availability of scan-
ning beam technology increases, so will potential for increased
conformality. This will very likely further increase the propor-
tion of patients who may beneﬁt from treatment with proton
therapy. As a ﬁeld, we will need to address the rapidly growing
disparity between clinical need for proton therapy, and the num-
ber of centers where robust, safe, and technically advanced therapy
is delivered. Delivery of this complex treatment requires massive
investment in not only treatment machines, but software and per-
sonnel (both physicists and clinicians) with deep understanding
and training with regard to its complexities. The nature of the pro-
ton beam and the uncertainties associated with it mandate that
physicians and physicists work as a team during each treatment
site implementation, and also to routinely analyze particularities
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of clinical cases whichmaywarrant different technical approaches.
Our obligation as a ﬁeld is to remain attentive to these issues as pro-
ton therapy burgeons from a tiny part of our ﬁeld to a technology
that may soon be available to beneﬁt large numbers of patients.
We must remain intellectually dedicated to examining the risks
and beneﬁts of this treatment with careful scientiﬁc methodology,
and clinically dedicated to utilizing the best technology available
for each of our patients.
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